PARP inhibitor Zejula (Niraparib tosylate monohydrate) outpaced its competitor Lynparza (Olaparib) in about 2 years. According to IQVIA, a pharmaceutical market research firm on the 31st, Zejula, Takeda's ovarian cancer treatment drug, recorded ￦3.5 billion in sales in the second quarter, surpassing Lynparza, which recorded ￦3.4 billion.
Zejula, which started its first sales in the fourth quarter of 2019, started to grow rapidly in December 2020. Sales jumped from around ￦1 billion last year to ￦3.2 billion in the first quarter of this year. In the second quarter, it increased by 289% year-on-year to ￦3.5 billion.

In the first quarter of last year, AstraZeneca's Lynparza, which previously d